CTM CRC is governed by an independent, skills-based board of directors.

The primary responsibility of the board of directors is to provide high-level governance for CTM CRC, financial accountability and oversight of compliance with Commonwealth and other appropriate laws and regulations. In addition to monitoring CTM CRC performance, the board plays an important role in the approval and regular review of CTM CRC funded projects to ensure that all CTM CRC research is aligned with its objectives.

CTM CRC has also established an audit and risk committee to assist the board in exercising due care, diligence and skill in discharging its oversight and monitoring responsibilities in relation to risk management, internal and external audit, financial statements and other matters.

Dr Leanna Read

Location: Adelaide, South Australia

Managing Director & Chair

Dr Leanna Read has extensive executive, board and investment experience in technology-based enterprises. She has a unique track record that spans the public and private sectors, particularly in biotechnology.

Dr Read is the founding chair of CTM CRC and has now taken on the additional role of CEO of CTM CRC, following the retirement of Dr Sherry Kothari in May, 2018.  Dr Read also chairs CTM CRC’s two spin-out companies, Carina Biotech Pty Ltd and TekCyte Pty Ltd.

Dr Read has been involved with the CRC sector since the scheme’s inception, with roles including CEO of the CRC for Tissue Growth and Repair, and board membership of two other CRCs. In 2001, Dr Read founded South Australian biotechnology company, TGR BioSciences Pty Ltd (a CRC spin- out), and served as the company’s Managing Director and CEO until 2012.

Dr Read held the position as Chief Scientist for South Australia for nearly four years, finishing her term in April 2018. She also brings extensive experience on boards that address innovation across the government, industry and academic sectors.  This includes current positions on the Federal Government Biomedical Translation Fund Committee and the board of biotechnology company, Biosensis Pty Ltd, as well as past membership of the South Australian Economic Development Board, the South Australian Science Council and the University of South Australia Council.

She is a Fellow of the Australian Institute of Company Directors and of the Australian Academy of Technological Sciences and Engineering, and has been the recipient of a number of prestigious local and national awards.



Dr Alexander Gosling AM

Location: Melbourne, Victoria

Non-executive director

Dr Alexander Gosling AM has been working in the field of process and product development for 40 years.

Dr Gosling holds a Masters in Engineering from the University of Cambridge and an honorary doctorate from Swinburne University of Technology. As a founding director of Invetech, an engineering and process development consultancy, he has serviced clients ranging from high tech start-ups to ‘smoke-stack industry’ global companies. He was part of the management team that led Invetech firstly to a public listing (as Vision Systems Ltd), and then to its acquisition by the US Danaher group for over $800M.

Dr Gosling is a past national president of the Australasian Industrial Research Group, a past national president of the Australia-Malaysia Business Council, a Fellow of the Academy of Technological Sciences and Engineering, a Fellow of the Institute of Engineers Australia, and a Governor of the Warren Centre for Advanced Engineering. He also sits on a number of industry advisory committees. He has been appointed a Member of the Order of Australia for services to business through innovative support for research and development, and to the community.

Currently, Dr Gosling is a Principal of Capstone Partners, a strategy consultancy specialising in technology commercialisation and the development of start-up companies. He is also on the board of the Innovative Manufacturing CRC and Micro-X Ltd, an early stage medical devices company.


Dr Sherry Kothari

Location: Lancashire, England

Non-executive director

Formerly CTM CRC’s CEO, Dr Sherry Kothari has been a founder-investor in two successful life sciences spin-out companies and brings extensive experience in working within bioscience at the research/industry clinical interface.

Dr Kothari started her career in maxillofacial surgery before undertaking a PhD in biomaterials and tissue engineering, followed by an MBA. As well as her interest and experience in medicine and the cell materials interface, Dr Kothari has a passion for entrepreneurship and translation within the biotechnology sector.

With a strong focus in strategic leadership, organisational culture and communication, Dr Kothari excels in working at cross-disciplinary boundaries to harness expertise within multidisciplinary teams to deliver tangible commercial outputs. Dr Kothari has established strategic partnerships across Australia, Asia, Europe and North America.

Dr Kothari is a recipient of the Women In Innovation SA Award (2014) for Science and Health and was a finalist in the 2016 Telstra Business Women’s Awards. Dr Kothari is a graduate of the Australian Institute of Company Directors as well as a member of the Regenerative Medicine Advisory Group for Ausbiotech, Australia’s biotechnology organisation.

Dr Sherry Kothari

Mr Charlie Latham

BSc.(Hons), CA, FCA
Location: Adelaide, South Australia

Non-executive director & Secretary / Audit & Risk Committee Member

Mr Charlie Latham is a Chartered Accountant with a background in science, finance and compliance. He has over 35 years professional experience across a broad range of industries including life sciences, manufacturing, engineering, investment and service industries.

Mr Latham began his career with an Honours degree in zoology, before transitioning to accounting, finance and auditing with professional accounting firms, including Deloitte. He has over 20 years’ experience of board involvement as Company Secretary and Chief Financial Officer (CFO) of small ASX listed entities.

He has served on a number of audit and risk committees, due diligence committees and capital raising committees, and has completed numerous acquisitions and disposals of businesses. He has also been a director and secretary of several private companies and subsidiaries of public companies.

Mr Latham has strong professional and government links in South Australia, and extensive networks within the Australian bioscience industry.



Dr Stephen Livesey

B.MedSci, PhD, MBBS
Location: Melbourne, Victoria

Non-executive director

Dr Stephen Livesey has a career history spanning medicine, medical research and commercialisation.

After graduating from his medical and postdoctoral studies at the University of Melbourne in 1985, he has held a number of positions in Australia and the US. In 1986, Dr Livesey co-founded LifeCell Corporation in the US, through a technology transfer from the University of Texas. The company was established to commercialise a cell and tissue preservation technology, which he invented (now marketed as AlloDerm™). 

Following a period in Australia as a Wellcome Trust Senior Research Fellow, Dr Livesey returned to the US to become Executive Vice President and Chief Science Officer of LifeCell. He was the lead scientist in securing additional funding for LifeCell, including venture capital, an initial public offering on the NASDAQ, private placements, follow-on offerings and public offerings, totaling approximately US$78M. AlloDerm has been used in more than two million surgical procedures with more than 600 peer-reviewed publications on its clinical and research use. In 2007, LifeCell Corporation

was acquired by Kinetic Concepts International (NYSE:KCI) for US$1.7bn.

In 2003, Dr Livesey returned to Australia and joined the Australian Stem Cell Centre, where he served as the Chief Scientific Officer and CEO. He maintains an active research interest in matrix-based research for spinal cord injuries, bone marrow transplantation and cartilage repair at St Vincent’s Hospital, Melbourne.


Mr Ray Wood

BSc.(Tech), FAICD
Location: Melbourne, Victoria

Non-executive director / Audit & Risk Committee Member

Mr Ray Wood has more than 35 year’s experience in developing and deploying Australian innovation and technology into global markets.

Mr Wood holds a BSc(Tech) Electronic Engineering. His experience ranges from the continuous flow pathology analysers of the early 1970’s and the first automated haematology counters, through to the development and marketing of diagnostic ultrasound machines, and, more recently, delivering professional consulting services and creating biotechnology spin outs.

Mr Wood has held roles within a range of organisations, including Plessy Telecommunications, Technicon Inc, Ausonics, PA Technology, Invetech and X-ray Technologies. He has significant experience in the integration of the code of cGMP, regulatory oversight and regenerative medicine.

Currently, Mr Wood holds a number of board positions including non-executive director of Cell Therapies Pty Ltd, director of the Victorian Clean Technology Fund and director and principal of Irendos Pty Ltd. He is a Fellow of the Australian Institute of Company Directors and of the Institute of Engineers Australia (ret).


Ms Suzanne Ridding

Location: Adelaide, South Australia

Audit & Risk Committee Member

Ms Suzanne Ridding is the external representative on the CTM@CRC Ltd Audit and Risk Committee. Ms Ridding is an experienced executive, sustainability consultant, banker, board director and company secretary. She has held leadership positions in private, public and not-for-profit sector organisations, internationally and in Australia. Ms Ridding has also managed her own successful sustainability consultancy business since 2008 specialising in organisation sustainability, in particular carbon management and climate change adaptation.

Ms Ridding was a non-executive director at the Risk Management Institution of Australasia for over three years. She has also worked extensively with boards and audit committees, including in her role as Chief Financial Officer and Company Secretary of TransAdelaide and as the Financial Controller at HomeStart Finance. 

Ms Ridding’s key skills and experience include strategy and policy development, extensive risk management, corporate governance, financial management and sustainability.


CTM CRC Management Team

Managing Director & Chair

Dr Leanna Read

Manager, Development & Commercialisation

Dr Tony Simula

Marketing & Communications Manager

Natalie Watkins

IP Counsel &
CEO, Carina Biotech

Dr Justin Coombs

Manager, Education & Industry Engagement

Dr Andrew Milligan

Project Manager

Katrina van Zanten

Manager, Business & Operations

Rosie Erasmus

Operations Manager, TekCyte

Dr Sue Low

Projects Manager, TekCyte

Dr Louise Smith

Administration Assistant

Paula Borlase